lung cancer news from FierceBiotech
NewsSPOTLIGHT: Avastin leaves ASCO ahead of Erbitux
Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Read more...
SPOTLIGHT: Antisoma gets $25M milestone from Novartis
Antisoma has received a $25 million milestone payment from Novartis, triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer. Read more...
Antisoma buys Xanthus for $52M
Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial Read more...
Avastin, Erbitux battle for lung cancer market
Genentech's stock was down this morning on results from a Phase III study of Avastin for non-small cell lung cancer. While the drug did meet the primary endpoint--an improvement in progression-free Read more...
ALSO NOTED: Arqule hires new CEO; Kosan launches mid-stage study; and much more...
> Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
ALSO NOTED: Antisoma gets $25M milestone; Takeda pays out retention bonuses; and much more...
> Novartis has kicked off a late-stage trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer, triggering a $25 million milestone payment to Antisoma. Read more...
Inhaled insulin lung cancer warning riles investors
The inhaled insulin field got blitzed again today after Nektar Therapeutics and Pfizer reported an increased number of Read more...
ALSO NOTED: Takeda, Abbott split TAP; Alseres raises funds; investigators close in on another case of drug counterfeiting;and m
> As expected, Takeda is paying Abbott $1.5 billion to disband a joint venture launched 30 years ago. In the deal to break up TAP, Abbott will keep the cancer drug Lupron and 300 sales people. Read more...
Kosan axes staffers (again), scouts for partners
Kosan Biosciences is laying off more than a third of its 91 workers as the developer concentrates its resources around its lead cancer therapies in a restructuring that has also shuffled its newly Read more...
SPOTLIGHT: Cancer drug flunks Phase III
BioNumerik Pharmaceuticals and ASKA Pharmaceutical said that a late-stage trial of Tavocept failed to produce a statistically significant response in patients with advanced non-small cell lung Read more...
| Press ReleasesPRESS RELEASE: ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study; Shares Soar NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company (NYSE: BMY - Read more... |
Get more lung cancer coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets